Nucleocytoplasmic β-catenin expression contributes to neuroendocrine differentiation in muscle invasive bladder cancer.
Polycomb repressive complex
bladder cancer
molecular subtype
neuroendocrine differentiation
transcriptomics
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
14 Jul 2024
14 Jul 2024
Historique:
revised:
17
06
2024
received:
16
02
2024
accepted:
26
06
2024
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
Bladder cancers are heterogeneous in nature, showing diverse molecular profiles and histopathological characteristics, which pose challenges for diagnosis and treatment. However, understanding the molecular basis of such heterogeneity has remained elusive. This study aimed to elucidate the molecular landscape of neuroendocrine-like bladder tumors, focusing on the involvement of β-catenin localization. Analyzing the transcriptome data and benefiting from the molecular classification tool, we undertook an in-depth analysis of muscle-invasive bladder cancers to uncover the molecular characteristics of the neuroendocrine-like differentiation. The study explored the contribution of transcription factors and chromatin remodeling complexes to neuroendocrine differentiation in bladder cancer. The study revealed a significant correlation between β-catenin localization and neuroendocrine differentiation in muscle-invasive bladder tumors, highlighting the molecular complexity of neuroendocrine-like tumors. Enrichment of YY1 transcription factor, E2F family members, and Polycomb repressive complex components in β-catenin-positive tumors suggest their potential contribution to neuroendocrine phenotypes. Our findings contribute valuable insights into the molecular complexity of neuroendocrine-like bladder tumors. By identifying potential therapeutic targets and refining diagnostic strategies, this study advances our understanding of endocrinology in the context of bladder cancer. Further investigations into the functional implications of these molecular relationships are warranted to enhance our knowledge and guide future therapeutic interventions.
Banques de données
RefSeq
['GSE253064']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
ID : 120C129
Organisme : European Molecular Biology Organization
ID : IG 4148
Informations de copyright
© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Dyrskjøt L, Hansel DE, Efstathiou JA, et al. Bladder Cancer. Nat Rev Dis Primers. 2023;9(1):58.
Meeks JJ, Al‐Ahmadie H, Faltas BM, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17:259‐270.
Al‐Ahmadie H, Netto GJ. Updates on the genomics of bladder cancer and novel molecular taxonomy. Adv Anat Pathol. 2019;27:36‐43.
Weinstein JN, Akbani R, Broom BM, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315‐322.
Grivas P, Bismar TA, Alva AS, et al. Validation of a neuroendocrine‐like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin‐based neoadjuvant chemotherapy. Urol Oncol. 2020;38(4):262‐268.
Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle‐invasive bladder cancer. Eur Urol. 2020;77(4):420‐433.
Lindskrog SV, Prip FF, Lamy P, Taber A, Clarice S. An integrated multi‐omics analysis identifies clinically relevant molecular subtypes of non‐muscle‐invasive bladder cancer. J Hematol Oncol. 2020;15(1):76.
Robertson AG, Kim J, Al‐ahmadie H, Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive molecular characterization of muscle‐invasive bladder cancer. Cell. 2017;171(3):540.
Costa B, Gibb EA, Bivalacqua TJ, et al. Molecular characterization of neuroendocrine‐like bladder cancer. Clin Cancer Res. 2019;25(13):3908‐3920.
Sanguedolce F, Calò B, Chirico M, Tortorella S, Carrieri G, Cormio L. Urinary tract large cell neuroendocrine carcinoma: diagnostic, prognostic and therapeutic issues. Anticancer Res. 2020;40:2439‐2447.
Eray A, Güneri PY, Yılmaz GÖ, Karakülah G, Erkek‐Ozhan S. Analysis of open chromatin regions in bladder cancer links β‐catenin mutations and Wnt signaling with neuronal subtype of bladder cancer. Sci Rep. 2020;10(1):18667.
An J, Woo HY, Lee Y, Kim HS, Jeong J, Kyum S. Clinicopathological features of 70 desmoid‐type fibromatoses confirmed by β‐catenin immunohistochemical staining and CTNNB1 mutation analysis. PLoS One. 2021;16:e0250619.
Braggio D, Zewdu A, Londhe P, et al. β‐Catenin S45F mutation results in apoptotic resistance. Oncogene. 2020;39(34):5589‐5600.
Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W. Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget. 2018;9(4):5492‐5508.
Hu X, Ruan Y, Cheng F, Yu W, Zhang X, Larré S. p130Cas, E‐cadherin and β‐catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol. 2011;18(9):630‐637.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114‐2120.
Liao Y, Smyth GK, Shi W. The subread aligner: fast, accurate and scalable read mapping by seed‐and‐vote. Nucleic Acids Res. 2013;41(10):e108.
Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078‐2079.
Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923‐930.
Mooney MA, Wilmot B. Gene set analysis: a step‐by‐step guide. Am J Med Genet B Neuropsychiatr Genet. 2015;168(7):517‐527.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge‐based approach for interpreting genome‐wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545‐15550.
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739‐1740.
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559.
Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25:25‐29.
Xie Z, Bailey A, Kuleshov MV, et al. Gene set knowledge discovery with Enrichr. Curr Protoc. 2021;1(3):e90.
von Mering C, Jensen LJ, Snel B, et al. STRING: known and predicted protein‐protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005;33:D433‐D437.
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498‐2504.
Shi Z, Qian X, Li L, et al. Nuclear translocation of β‐catenin is essential for glioma cell survival. J Neuroimmune Pharmacol. 2012;7(4):892‐903.
Von Bülow C, Hayen W, Hartmann A, Mueller‐Klieser W, Allolio B, Nehls V. Endothelial capillaries chemotactically attract tumour cells. J Pathol. 2001;193(3):367‐376.
Verheul TCJ, van Hijfte L, Perenthaler E, Barakat TS. The why of YY1: mechanisms of transcriptional regulation by yin Yang 1. Front Cell Dev Biol. 2020;8:592164.
Rabbani F, Richon VM, Orlow I, et al. Prognostic significance of transcription factor E2F‐1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst. 2009;91:874‐881.
Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9:785‐797.
Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19:326‐338.
Ismaili N. A rare bladder cancer – small cell carcinoma: review and update. Orphanet J Rare Dis. 2011;6:75.
Valenta T, Hausmann G, Basler K. The many faces and functions of Î 2‐catenin. EMBO J. 2012;31:2714‐2736.
Rosenbloom AB, Tarczy nski M, Lam N, Kane RS, Bugaj LJ, Schaffer DV. β‐Catenin signaling dynamics regulate cell fate in differentiating neural stem cells. Proc Natl Acad Sci U S A. 2020;117(46):28828‐28837.
Lissa D, Takahashi N, Desai P, et al. Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient‐derived models. Nat Commun. 2022;13(1):2023.
Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol. 2014;4:60.
Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1727‐1733.
Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104‐121.
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323‐5335.
Shi Y, Qian ZR, Zhang S, et al. Cell cycle protein expression in neuroendocrine tumors: association of CDK4/CDK6, CCND1, and phosphorylated retinoblastoma protein with proliferative index. Pancreas. 2017;46(10):1347‐1353.
Castro DS, Martynoga B, Parras C, et al. A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome‐wide characterization of its targets. Genes Dev. 2011;25(9):930‐945.
Lan MS, Breslin MB. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J. 2009;23(7):2024‐2033.
Davies A, Zoubeidi A, Selth LA. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Endocr Relat Cancer. 2020;27:R35‐R50.
Liu R, Xu Z, Huang X, Xu B, Chen M. Yin Yang 1 promotes the neuroendocrine differentiation of prostate cancer cells via the non‐canonical WNT pathway (FYN/STAT3). Clin Transl Med. 2023;13(10):e1422.
Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev. 2000;14:804.
German B, Ellis L. Polycomb directed cell fate decisions in development and cancer. Epigenomes. 2022;6:28.
Santos M, Martínez‐Fernández M, Dueñas M, et al. In vivo disruption of an Rb‐E2F‐Ezh2 signaling loop causes bladder cancer. Cancer Res. 2014;74(22):6565‐6577.
Martínez‐Fernández M, Rubio C, Segovia C, López‐Calderón FF, Dueñas M, Paramio JM. EZH2 in bladder cancer, a promising therapeutic target. Int J Mol Sci. 2015;16:27107‐27132.
Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15:271‐286.